|
AU2005285040A1
|
|
D-methionine formulation with improved biopharmaceutical properties
|
|
WO2006010083A2
|
|
Biodegradable nanoparticles
|
|
WO2005120489A2
|
|
Treatment of central nervous system disorders or injuries with d-methionine
|
|
US2005196343A1
|
|
Degradable nanoparticles
|
|
ZA9000468B
|
|
An expression system for production of chimeric monoclonal antibodies
|
|
IL93118D0
|
|
Expression vectors,cells transformed thereby and their use in the production of chimeric monoclonal antibodies
|
|
ZA8907338B
|
|
Therapeutics for aids based on inhibitors of hiv protease
|
|
IE893097L
|
|
Amino acid derivatives
|
|
EP0361341A2
|
|
Therapeutics for aids based on inhibitors of HIV protease
|
|
ZA8906668B
|
|
A human rhinovirus receptor protein that inhibits virus infectivity
|
|
IE892805L
|
|
Human rhinovirus receptor protein
|
|
US5151508A
|
|
Promoter region for DNA sequences which encode the precursor of the human A4 amyloid protein
|
|
US5235049A
|
|
Nucleic acid sequences encoding a soluble molecule (SICAM-1) related to but distinct from ICAM-1
|
|
US5015570A
|
|
Molecular diagnosis of Alzheimer Disease
|
